Published in Cancer Weekly, October 24th, 2000
The biological license application (BLA) will be based predominantly on data from the recently completed Phase III study of the use of Melacine vaccine for the treatment of Stage II melanoma, which started enrollment in April of 1992 and has followed patients through January of 2000. The filing will also contain data following the same group of patients through January of 2001.
The results of this study, conducted by the former Ribi Immunochem Research, Inc., (acquired...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.